Correlation Between Expression of HIF-1α and Prognosis of Arsenic-containing Chinese Herbal Compound in Treatment of Myelodysplastic Syndrome
10.13422/j.cnki.syfjx.20241295
- VernacularTitle:HIF-1α表达与含砷中药复方治疗骨髓增生异常综合征的预后生存相关性
- Author:
Peizhen JIANG
1
;
Xiupeng YANG
1
;
Dexiu WANG
1
;
Wenru WANG
2
;
Yan LYU
1
;
Weiyi LIU
1
;
Zhuo CHEN
1
;
Hongzhi WANG
1
;
Xiaoqing GUO
1
;
Shanshan ZHANG
1
;
Yonggang XU
1
;
Xudong TANG
1
Author Information
1. Xiyuan Hospital， China Academy of Chinese Medical Sciences，Beijing 100091，China
2. Dongfang Hospital， Beijing University of Chinese Medicine，Beijing 100078，China
- Publication Type:Journal Article
- Keywords:
myelodysplastic syndromes;
hypoxia-inducible factor-1α（HIF-1α）;
arsenic-containing Chinese herbal compound;
Qinghuang powder;
survival prognosis
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(9):101-107
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveMyelodysplastic syndromes （MDS） is a group of clonal hematopoietic stem cell disorders，and this study aims to investigate the expression of hypoxia-inducible factor-1α（HIF-1α） in the bone marrow cells of patients with MDS and its correlation with the clinical features of MDS，the therapeutic efficacy of arsenic-containing Chineseherbal compound，and the survival prognosis. MethodAccording to the inclusion and exclusion criteria，27 MDS patients treated with arsenic-containing Chinese herbal compound in the Department of Hematology，Xiyuan Hospital，China Academy of Chinese Medical Sciences from January 2022 to September 2022 were included，and their bone marrow samples were collected by myelotomy. HIF-1α expression level in bone marrow cells was detected by real-time polymerase chain reaction （PCR） to analyze its correlation with clinical features，and logistic and Cox regression was used to analyze the risk factors affecting the efficacy and prognostic survival of MDS patients. ResultThe HIF-1α mRNA expression level was lower in bone marrow cells of MDS patients than in healthy subjects. HIF-1α was positively correlated with the degree of myelodysplasia（r=0.384，P<0.05） and bone marrow granulocytic system%（G%）（r=0.560，P<0.01）. Logistic regression showed that HIF-1α was a risk factor for the prognosis in the follow-up of the efficacy of treatment（P<0.05）and Cox regression showed that HIF-1α was an independent factor affecting the survival prognosis of MDS patients ［odds ratio（OR）=398.968，95% confidence interval（CI）（1.281，116 858.743），P<0.05］. ConclusionThe level of HIF-1α expression in bone marrow cells of MDS patients was closely related to the degree of clinical myelodysplasia and G%，and HIF-1α was a risk factor for the efficacy for and survival prognosis of MDS patients.
